A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...
A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...
Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...
Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...
The Zacks Medical - Biomedical and Genetics industry, to which CRISPR Therapeutics belongs, has gained 7% over this period.
CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...
The bioscience industry has been rapidly expanding with research, people, and ideas. This year’s third annual Bioscience Summit brings together those ideologies and more. “We just want to understand ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback